Portfolio companies news

11 June 2015

Atlas Genetics participates in £1.5m Grant Funding Award

Atlas Genetics Ltd (“Atlas” or the “Company”), the ultra-rapid ‘test and treat’ molecular diagnostics company, today announces a collaboration with St George’s, University of London to develop and evaluate DNA-based point of care tests which can simultaneously detect both infection and antibiotic resistance in a patient within the same clinical visit.

11 June 2015

Celtaxsys Presents Clinical Data on Oral CTX-4430 at 2015 European Cystic Fibrosis Conference: Positive Impacts on Key Biomarkers in Patients with CF

Celtaxsys, a clinical stage drug development company focused on advancing care for patients suffering from inflammatory diseases, including those with rare and orphan inflammatory diseases, announced today data from Phase 1 clinical trials of CTX-4430 will be presented at the 2015 Meeting of the European Cystic Fibrosis Society in Brussels on Friday, Jun 12, 2015.

08 June 2015

Celtaxsys Secures $45M in Capital to Fund Novel Anti-inflammatory Phase 2 Programs in Cystic Fibrosis and Acne

Celtaxsys, a clinical stage drug development company focused on developing novel therapies for patients suffering from inflammatory diseases, today announced the successful completion of a $40M Series D financing led by Domain Partners VIII.  Additional investors in the financing include Lumira Capital, RMI Partners, Masters Capital Management and the Georgia Research Alliance Venture Fund.

08 June 2015

Tobira Therapeutics Completes Patient Recruitment for CENTAUR Phase 2b Study of Cenicriviroc in NASH with Liver Fibrosis

Tobira Therapeutics, Inc. (NASDAQ: TBRA), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel treatments for liver and inflammatory diseases, announced today that it has completed recruitment for the Phase 2b CENTAUR study. CENTAUR is a global, double blind, placebo controlled, Phase 2b clinical trial evaluating the treatment effects of cenicriviroc (CVC) versus placebo in patients with non-alcoholic steatohepatitis (NASH) and liver fibrosis at high risk of progressive disease. NASH is a severe form of non-alcoholic fatty liver disease. Patients with NASH and risk factors such as liver fibrosis and type 2 diabetes or metabolic syndrome are often at higher risk for progression to more advanced liver complications such as cirrhosis and liver cancer. Results of the one-year primary endpoint are anticipated to be announced in mid-2016.

02 June 2015

Celtaxsys Inc. Receives $5M Research Award to Advance Once Daily, Oral Anti-Inflammatory Medicine into Phase 2 CF Patient Lung Function Preservation Trial

Celtaxsys, a clinical stage drug development company focused on advancing care for patients suffering from inflammatory diseases, including those with rare and orphan inflammatory diseases, announced today that it has received a development award for $5 million from Cystic Fibrosis Foundation Therapeutics, Inc. ("CFFT"), the non-profit drug discovery and development affiliate of the Cystic Fibrosis Foundation The development award will help support a Phase 2 clinical trial of the Company's lead development candidate, a once daily, oral anti-inflammatory drug CTX-4430 in adults with cystic fibrosis ("CF"). CTX-4430 is a selective inhibitor of Leukotriene A4 Hydrolase that targets re-balancing of a patient's over activated inflammatory response without increasing susceptibility to infection. CTX-4430 has been granted orphan status for CF in both the US and the EU. 

01 June 2015

Epic Sciences Expands Silicon Valley Bank Credit Facility

Epic Sciences, Inc., a private diagnostics company that designs and develops products and offerings to personalize and advance the treatment and management of cancer, announced today that it has expanded the available credit under its existing credit facility with Silicon Valley Bank (SVB).  The amended agreement increases the available capacity of the facility from $5 million to $15 million and has extended the maturity by 27 months to April 1, 2019.  

29 May 2015

Genetic Analysis of Single Circulating Tumor Cells Shows High Intra-patient Heterogeneity

Epic Sciences announced today that the company will present single cell sequencing data, from metastatic castrate resistant prostate cancer patients, at the 2015 annual meeting of the American Society for Clinical Oncology. This application expands the investigational utility of Epic Sciences' no cell left behind™ platform to characterize circulating tumor cell (CTC) genomic alterations. The study revealed that late stage patients have heterogeneous clonal CTC populations harboring separate genetic alterations. 

27 May 2015

NovaMedica is Expanding Ophta Horizons

NovaMedica, a Russian pharmaceutical company, participated in the White Nights-2015 International Ophthalmology Congress and hosted a satellite symposium “NovaMedica: New Ophta Horizons”. The symposium was started by Boris Malyugin, Deputy General Director for Science at MNTK “Eye Microsurgery” named after Federov S.N., and presented the first publication of in vitro research results on potency of netilmicin and reference drug products.

18 May 2015

Marinus Pharmaceuticals Presents Clinical Data of Ganaxolone in Pediatric Epilepsies at Antiepileptic Drug and Device Trials XIII Conference

Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative epilepsy and other neuropsychiatric therapeutics, announced that Gail M. Farfel, Ph.D., Chief Clinical and Regulatory Officer of Marinus, presented clinical data on ganaxolone in drug-resistant pediatric epilepsies at the Antiepileptic Drug and Device Trials (AED) XIII conference on Friday, May 15, 2015.

14 May 2015

Neothetics Reports First Quarter 2015 Financial Results

Neothetics, Inc.  (Nasdaq:NEOT), a clinical-stage specialty pharmaceutical company developing therapeutics for the aesthetic market, today reported financial results for the first quarter 2015.